10
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Embed Size (px)

Citation preview

Page 1: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.

Chapter 73

Drug Therapy of Rheumatoid Arthritis

Page 2: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 2

Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) Autoimmune inflammatory disorder

Treatment Relieve symptoms Maintain joint function Minimize systemic involvement Delay progression of disease

Page 3: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 3

Classes of Antiarthritic Drugs

NSAIDs Nonsteroidal anti-inflammatory drugs

DMARDs Disease-modifying antirheumatic drugs

Glucocorticoids Adrenal corticosteroids

Page 4: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 4

Drug Selection for Rheumatoid Arthritis

Protocol Start with NSAIDs If symptoms persist, add DMARDs Glucocorticoids may be added until DMARDs take

effect

Page 5: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 5

DMARDs I: Major Nonbiologic DMARDs

Methotrexate Sulfasalazine

Page 6: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 6

Methotrexate

Most rapid-acting DMARD Therapeutic effect: 3 to 6 weeks Adverse effects

Hepatic fibrosis Bone marrow suppression GI ulceration Pneumonitis

Page 7: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 7

Sulfasalazine

Used to treat inflammatory bowel disease (IBD); now used for RA as well Anti-inflammatory and immunomodulatory actions Can slow progression of joint deterioration GI side effects may be intolerable

Page 8: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 8

Other DMARDs I: Major Nonbiologic DMARDs

Leflunomid (Arava) Hydroxychloroquine (Plaquenil)

Page 9: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 9

DMARDs II: Major Biologic DMARDs

Tumor necrosis factor inhibitors Suppress immune function Pose risk of serious infection Work by neutralizing tumor necrosis factor (TNF)

• Etanercept (Enbrel)• Infliximab (Remicade)• Adalimumab (Humira)

Page 10: Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. 10

Etanercept

New DMARD Inactivates TNF

Use Moderate to severe RA

Adverse effects Infection (may be serious) Injection-site reactions Tuberculosis Heart failure Cancer Other adverse effects